Risk of exacerbation and pneumonia with single inhaler triple versus dual therapy in IMPACT

M. Dransfield (Birmingham, United States of America), C. Crim (Research Triangle Park, United States of America), G. Criner (Philadelphia, United States of America), D. Halpin (Exeter, United Kingdom), M. Han (Ann Arbor, United States of America), C. Jones (Research Triangle Park, United States of America), S. Kilbride (Stockley Park West, United Kingdom), P. Lange (Copenhagen, Denmark), D. Lipson (King of Prussia, United States of America), D. Lomas (London, United Kingdom), F. Martinez (New York, United States of America), D. Singh (Manchester, United Kingdom), R. Wise (Baltimore, United States of America)

Source: International Congress 2018 – Integrating pharmacological and non-pharmacological management in COPD: are we there yet?
Disease area: Airway diseases

Congress or journal article abstractWebcastSlide presentationE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
M. Dransfield (Birmingham, United States of America), C. Crim (Research Triangle Park, United States of America), G. Criner (Philadelphia, United States of America), D. Halpin (Exeter, United Kingdom), M. Han (Ann Arbor, United States of America), C. Jones (Research Triangle Park, United States of America), S. Kilbride (Stockley Park West, United Kingdom), P. Lange (Copenhagen, Denmark), D. Lipson (King of Prussia, United States of America), D. Lomas (London, United Kingdom), F. Martinez (New York, United States of America), D. Singh (Manchester, United Kingdom), R. Wise (Baltimore, United States of America). Risk of exacerbation and pneumonia with single inhaler triple versus dual therapy in IMPACT. 1991

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you: